A 2025 review showed that SARMs are correlated with improvements in physical performance and body composition, but their safety profile is still unclear
Given that GLP-1 receptor agonists require sustained exposure for cardiovascular and renal benefits (2, 3), understanding treatment initiation effects may have limited clinical use in this complex post-transplant milieu, in which multiple factors influence outcomes
Reported benefits (per available research): FDA-approved, clinical-trial-supported reduction of excess visceral abdominal fat in HIV-associated lipodystrophy, the only indication with robust human RCT evidence behind it Studied in a randomized, placebo-controlled trial for possible support of executive function and cognitive performance in healthy older adults and adults with mild cognitive impairment (Baker et al., 2012) Proposed, but far less rigorously studied in healthy or bodybuilding populations, to support lean body mass and body composition changes through GH/IGF-1 axis stimulation
If your pharmacy used a salt form and dosed it as if it were base semaglutide, you could be getting substantially less active drug than intended
The PP1-R6 protein phosphatase holoenzyme is involved in the glucose-induced dephosphorylation and inactivation of AMP-activated protein kinase, a key regulator of insulin secretion, in MIN6 beta cells